Bayer statement on glyphosate and honey bee health

Bayer statement on glyphosate and honey bee health

Leverkusen, September 25, 2018 – No large-scale study has ever found a link between glyphosate and honey bee health issues. A new paper published in the Proceedings of the National Academy of Sciences does not change that. This paper links the use of glyphosate to gut microbe problems in honey bees. The paper does not provide any evidence that the purported effects could have a negative impact on bee health under realistic field conditions. It is also questionable whether the concentrations of the substance tested could at all be absorbed by bee populations in the open over a relevant period of time. At the same time, this research team did not discuss these new findings in light of their previous work, according to which antibiotics that beekeepers use in their hives are the cause of altered gut microbe communities in honey bees.

Furthermore, the paper relied on a relatively small number of individual bees which were tested. However, it is only possible to provide a realistic assessment of the extent to which the observed effects might play a role in a real-life scenario by conducting studies with entire bee colonies in the field. Furthermore, regulatory studies on pesticides have to follow strict international guidelines developed by the Organization of Economic Cooperation and Development (OECD) and other international organizations and include endpoints that are relevant to the protection of honey bees. The published paper does not meet the criteria stipulated in these guidelines.

Cautionary Statements Regarding Forward-Looking Information

Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: the risk that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected timeframes (or at all) and to successfully integrate the operations of Monsanto Company (“Monsanto”) into those of Bayer Aktiengesellschaft (“Bayer”); such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater or more significant than expected following the transaction; the retention of certain key employees at Monsanto; the parties’ ability to meet expectations regarding the accounting and tax treatments of the merger; the impact of refinancing the loans taken out for the transaction; the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on Bayer’s rating of indebtedness; the effects of the business combination of Bayer and Monsanto, including the combined company’s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) for the fiscal year ended August 31, 2017, and Monsanto’s other filings with the SEC, which are available at and on Monsanto’s website at; and other factors discussed in Bayer’s public reports which are available on the Bayer website at Bayer assumes no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.